Home › Trial NCT06048926
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
- Trial IDNCT06048926
- StatusEnrolling By Invitation
- PhaseN/A
- Study typeInterventional
- SponsorThe First Affiliated Hospital with Nanjing Medical University
- Enrollment30
- Start date2022-07-30
- ConditionsEsophageal Squamous Cell Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.